本帖最后由 老马 于 2013-3-13 13:43 编辑 . k; s% T! P( c5 L" G6 `5 E! v
/ L& H5 ?, ?8 O8 }5 u9 F) L0 _# a健择（吉西他滨）+顺铂+阿瓦斯汀
( I* y7 [6 d7 r7 M8 l0 c0 L Gemzar +Cisplatin + Avastin
" {; F: Y/ J' Y6 S! e( bhttp://annonc.oxfordjournals.org/content/21/9/1804.full
# ?" r3 N- Z [Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) ) w( \6 V+ S; l2 b' P+ [! B; E J$ l
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
9 r; W3 }( B& P8 w1 FResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
, s$ P1 V7 u, D Q
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 284)
5 K8 C% W$ E$ r) v+ G
华为网盘附件：
% I2 C' d: {5 _6 H! d/ i【华为网盘】ava.JPG8 |0 x6 |% H5 S8 X
|
显身卡
